Alkermes enters the final week of June with a striking split: the stock has surged 30% in a month, analysts are chasing it higher with fresh target upgrades, yet a 10.4% short interest reading signals that a meaningful cohort of investors still isn't convinced.
The analyst bid is the clearest story this week. Targets have moved sharply higher in rapid succession — Needham raised to $61 just this week, following its own lift to $54 six days earlier. TD Cowen moved its target from $42 to $50 on Monday. RBC Capital lifted to $56 earlier in the month. Every recent action across the coverage universe has been a raise, not a cut, with all firms maintaining positive ratings. The mean consensus target now sits at $48.13 — roughly in line with the current price of $48.07 — which means the Street has effectively been chasing rather than leading the move. The sole holdout is Bank of America, which carries a Neutral rating with a $36 target that now sits well below the stock; that gap is the bear camp's last visible foothold on the Street.
The bull thesis centres on Alkermes' profitable core. Marketed drugs Aristada and Vivitrol are expected to generate over $300M in adjusted EBITDA this year, and the company's pipeline carries optionality through ALKS 2680, an OX2R agonist in Phase 2b studies for narcolepsy and idiopathic hypersomnia. The bear case is narrower but pointed: delays in that Phase 2b programme risk pushing out the next meaningful catalyst, and competition in the sleep-disorder space is intensifying. The EPS surprise factor score ranks in the 99th percentile — the company has consistently beaten estimates — but 30-day and 90-day EPS momentum scores of 3 and 9 respectively suggest the forward earnings revision trend has been modest rather than explosive. A trailing PE that has expanded by roughly 15 turns over the past month to 35.9x captures how much valuation has moved with the price.
Short positioning tells a more cautious story about the durability of the rally. At 10.4% of free float, short interest is genuinely elevated for a profitable mid-cap biotech. The good news for bulls is that shorts have been retreating — SI has fallen about 10% over the past month, from roughly 19.7M shares to 17.2M. The lending market is loose: borrow availability runs at 474%, meaning there are nearly five shares available for every one already lent out, and the cost to borrow is negligible at 0.53%. That combination — high but declining SI, easy borrow conditions — points to orderly short covering rather than a squeeze dynamic. Days-to-cover of 8.45 is the one lingering friction; exiting the short book is not a one-day exercise.
Options traders have turned notably more relaxed. The put/call ratio has dropped to 0.64, below its 20-day average of 0.72, and the z-score is mildly negative — a reversal from the more defensive posture that prevailed through most of May, when the PCR was running close to 0.90 or above. Peers provide some context on the week's broader tone: SRRK and AUPH both added roughly 11–12% on the week, suggesting sector momentum is broadly supportive rather than uniquely Alkermes-driven. FDMT was the standout, jumping 26% — though that move likely reflects its own binary event rather than read-across.
Insider activity since May has been uniformly selling, with the CMO, CLO, and acting CAO all trimming positions at prices in the low-to-mid $40s. The aggregate 90-day net is technically positive at roughly 65,000 shares, but that reflects a Director award rather than open-market buying. None of the sells carry high significance scores, and all appear to be modest position management rather than a coordinated exit — but the absence of any insider purchase into the 30% monthly rally is a data point worth noting.
Q1 earnings in May produced a 3.4% day-one gain and a 12% five-day move, reinforcing a pattern of the stock rewarding positive prints with sustained follow-through. The next earnings date is July 27. Between now and then, the key variable is whether the analyst consensus — currently sitting right at the stock price — develops enough headroom to sustain momentum, or whether the gap between target and price simply narrows as the Street runs out of room to upgrade.
See the live data behind this article on ORTEX.
Open ALKS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
